Tresiba vs. Lantus: Duration, Flexibility, and Night Lows

Tresiba (insulin degludec) and Lantus (insulin glargine U100) both provide once-daily background insulin coverage, and they lower blood sugar to roughly the same degree. Where they differ most is in how long they last in the body, how steady their effect is from one day to the next, and how often they cause low blood sugar, particularly overnight. Tresiba consistently shows lower rates of hypoglycemia across clinical trials, while Lantus has decades of real-world track record and a lower upfront price tag.

How They Work Under the Skin

Both insulins are injected into the fat layer just below the skin, but what happens next is different. Lantus forms tiny crystals called microprecipitates in the slightly acidic tissue. These crystals dissolve gradually, releasing insulin over roughly 24 hours. In studies tracking how fast the insulin leaves the injection site, about half the dose of Lantus was still present after around 26 hours, and a quarter remained even at about 42 hours, making its absorption about two to three times slower than older NPH insulin.¹

Tresiba takes a fundamentally different approach. After injection, its molecules link together into long chains of multi-hexamers, forming a slow-release depot. From that depot, individual insulin molecules peel off at an unusually steady rate. The result is a half-life exceeding 25 hours and a total duration of action beyond 42 hours at steady state.² That extra-long tail is the key pharmacological difference: it creates a larger buffer of active insulin in the body at any given time, which smooths out the peaks and valleys between doses.³

Day-to-Day Steadiness

One of the practical consequences of Tresiba’s longer action is more consistent blood sugar levels from one day to the next. A pharmacodynamic comparison found that the day-to-day variability in glucose-lowering effect was significantly lower with Tresiba than with both Lantus U100 and its concentrated sibling, glargine U300.⁴ In a continuous glucose monitoring study of people with type 1 diabetes who switched from Lantus to Tresiba, the average size of blood sugar swings dropped significantly, and time spent below 70 mg/dL also fell.⁵

Not every study, however, has found a dramatic difference. A small randomized crossover trial in Japanese patients with type 1 diabetes found no significant difference in 24-hour mean glucose or the standard deviation of glucose readings between the two insulins.⁶ The bigger studies tend to favor Tresiba for variability, but the advantage may be more meaningful for people whose blood sugar is particularly hard to stabilize.

Hypoglycemia, Especially at Night

This is where the clinical difference between the two insulins is most pronounced and most studied. Hypoglycemia during sleep is especially dangerous because you are less likely to notice the warning signs, and it can ruin sleep quality even when the episode is mild. In the SWITCH 1 trial, which enrolled people with type 1 diabetes, the rate of nighttime symptomatic low blood sugar was about 36% lower with Tresiba compared with Lantus during the maintenance period. Roughly a third of patients on Tresiba had nighttime episodes versus over 43% on Lantus.⁷

The pattern held for type 2 diabetes as well. In the SWITCH 2 trial, overall symptomatic hypoglycemia was about 30% lower with Tresiba, and nocturnal episodes dropped by roughly 42%. About 10% of patients on Tresiba experienced nighttime lows compared with nearly 15% on Lantus.⁸ A meta-analysis pooling multiple randomized trials confirmed the trend: during maintenance periods, all confirmed hypoglycemia was about 19% lower with Tresiba, and confirmed nocturnal hypoglycemia was about 35% lower, with the differences being more pronounced in type 2 diabetes than type 1.⁹

In one of the earlier treat-to-target trials (BEGIN Once Long), which followed insulin-naive type 2 diabetes patients for a year, overall confirmed hypoglycemia rates were fairly similar between the two groups, but nocturnal confirmed events were significantly less common with Tresiba, occurring at roughly two-thirds the rate seen with Lantus.¹⁰ The consistent finding across all these studies is that Tresiba’s advantage is most visible at night and becomes more apparent during the maintenance phase, after doses have been titrated to target.

Real-world data also supports this advantage. A prospective study of patients switching from other basal insulins to Tresiba found significant drops in hypoglycemia rates across the board. In type 1 diabetes, severe hypoglycemia fell by roughly 72%, and nocturnal episodes dropped by about 39%. In type 2 diabetes, overall hypoglycemia fell by more than half after the switch.¹¹

Blood Sugar Control and Weight

When it comes to actually lowering HbA1c, the two insulins perform almost identically in head-to-head trials. In the one-year BEGIN Once Long trial, both achieved similar reductions in HbA1c from baseline. Weight gain was also comparable: about 2.4 kg with Tresiba and 2.1 kg with Lantus, a difference that was not statistically meaningful.¹² A two-year extension of a similar trial confirmed the parity: overall hypoglycemia, weight gain (about 2.7 vs. 2.4 kg), and average daily insulin dose were all essentially the same between the two insulins.¹³

If your primary concern is getting your HbA1c down, you can expect both insulins to do the job about equally well. And neither one is noticeably worse for weight gain than the other.

Cardiovascular Safety

The large DEVOTE trial was designed specifically to test cardiovascular safety in people with type 2 diabetes at high risk for heart attacks and strokes. Over its course, major cardiovascular events occurred in about 8.5% of the Tresiba group and 9.3% of the Lantus group, establishing that Tresiba was at least as safe as Lantus for heart health. The trial also showed that severe hypoglycemia was significantly less common with Tresiba: roughly 4.9% of patients versus 6.6% with Lantus, a 40% relative reduction in the rate of severe lows.¹⁴ A subanalysis of DEVOTE looking specifically at patients aged 65 and older found the cardiovascular safety profile and the hypoglycemia advantage both held up regardless of age.¹⁵

The Flexibility Factor

Lantus works best when injected at the same time every day. Miss your window by a few hours and you may notice the difference. Tresiba’s ultra-long duration creates a more forgiving schedule. The BEGIN Flex T1 trial tested this directly by forcing some patients to vary their injection times by as much as 8 to 40 hours between doses. Over 26 weeks, HbA1c reductions were similar whether Tresiba was injected on a fixed or flexible schedule, and both were noninferior to a fixed Lantus regimen. Nocturnal hypoglycemia was actually 40% lower in the forced-flexible Tresiba group compared with the fixed Lantus group. After a year, patients allowed to choose their own injection times freely still maintained comparable HbA1c, with 25% less nocturnal hypoglycemia than the Lantus group.¹⁶

For people with unpredictable schedules — shift workers, frequent travelers, teenagers — this flexibility is genuinely useful. Lantus can still be adjusted somewhat, but the official labeling and clinical data support Tresiba’s tolerance for wider timing variation.

Children and Adolescents

Tresiba is approved for children as young as one year old, making it one of the few ultra-long-acting insulins with pediatric clearance, and studies have shown that its pharmacokinetics in children are equivalent to those in adults.¹⁷ Lantus is also widely used in pediatric diabetes but does not carry the same formal labeling for very young children in all markets. In a study of children and adolescents with type 1 diabetes who switched from Lantus to Tresiba, fasting blood glucose improved and no severe hypoglycemia episodes occurred. The researchers also noted that basal insulin doses could be reduced after switching, and mealtime insulin doses also came down.¹⁸

The flexibility advantage may matter even more for children. Getting a toddler or teenager to inject at the exact same time every day is a battle many families know well, and Tresiba’s forgiving dosing window can take some of the stress out of the routine.

Kidney Disease and Older Adults

People with kidney disease metabolize insulin differently, and hypoglycemia risk goes up as kidney function declines. Some clinical data has suggested Tresiba may be safer in this population. A poster comparing the two insulins in patients with stage 3 and stage 4 chronic kidney disease found that among the sickest group (stage 4), Tresiba was associated with substantially fewer hypoglycemic episodes — 9 versus 26 in the Lantus group — and no nocturnal events at all.¹⁹

However, the picture is more complicated than it first appears. A large population-based study of older adults with diabetes and chronic kidney disease found the opposite: Tresiba was actually associated with a higher rate of hospital visits for hypoglycemia than Lantus over 180 days, with roughly 1% of Tresiba users experiencing such an event compared with about 0.7% on Lantus. The authors cautioned that the safety advantages seen in controlled clinical trials may not fully translate to older adults with kidney disease in everyday clinical practice.²⁰ This is a reminder that trial populations and real-world populations are not the same. Older patients with kidney disease often take multiple medications, have irregular eating patterns, and face other complications that can amplify hypoglycemia risk regardless of which insulin they use.

Cost and Value

In the United States, Tresiba carries a higher list price than Lantus (and its biosimilars), which is often the deciding factor when insurance coverage is limited. Several economic analyses from other healthcare systems have tried to account for the full picture, including the costs of hypoglycemic events, emergency room visits, and quality-of-life differences.

A U.S.-based economic model found Tresiba to be dominant — meaning more effective and less costly overall — versus Lantus for type 1 diabetes and for type 2 patients on basal-only regimens, mainly because reduced severe hypoglycemia events offset the higher drug cost. For type 2 patients on basal-bolus therapy, Tresiba was cost-effective though not dominant.²¹ Similar conclusions came out of UK and Spanish analyses, with the savings driven primarily by fewer severe and nocturnal hypoglycemic events.²²²³

These models are sensitive to local pricing, though. In a system where Lantus biosimilars are cheap and hypoglycemia events are relatively rare (as in well-educated, well-monitored patients), the economic case for Tresiba becomes weaker. For someone with frequent lows, erratic schedules, or a history of severe episodes, the calculus tilts more strongly toward Tresiba.

Real-World Evidence Beyond Trials

Randomized trials are the gold standard, but they enroll carefully selected patients who are closely monitored. Real-world studies fill in some of the gaps. A retrospective comparison from India found that patients starting Tresiba achieved similar HbA1c reductions to those starting Lantus, but with significantly fewer patient-reported hypoglycemic episodes (12 versus 40) and a lower daily insulin dose.²⁴ A larger comparative effectiveness study of insulin-naive type 2 diabetes patients found Tresiba associated with a greater HbA1c reduction (by about 0.27 percentage points) and a 30% lower rate of hypoglycemia compared with glargine U300, a newer concentrated version of the Lantus molecule. Patients on Tresiba were also 27% less likely to stop treatment.²⁵

Switching Between the Two

If you and your doctor decide to switch from Lantus to Tresiba or vice versa, the general guidance is straightforward: start the new insulin at the same unit dose you were taking of the old one. But expect some turbulence in the first couple of weeks. Because the insulins have different durations and absorption profiles, your fasting blood sugar may run higher or lower than usual while a new steady state establishes. Clinical guidance recommends checking blood sugar more often during this transition period and being cautious with high-risk activities like driving or vigorous exercise until your readings stabilize.²⁶

The Combination Products

Both Tresiba and Lantus serve as the basal insulin backbone in fixed-ratio combination pens that pair insulin with a GLP-1 receptor agonist. Tresiba is combined with liraglutide in a product called Xultophy (iDegLira), while Lantus is combined with lixisenatide in Soliqua (iGlarLixi). These combination products are designed for people with type 2 diabetes who need both basal insulin and a GLP-1 drug, bundled into a single daily injection.

Head-to-head data between iDegLira and iGlarLixi is limited to indirect comparisons, since no single trial has randomized patients directly between them. A systematic literature review and indirect comparison suggested iDegLira lowered HbA1c by about 0.36 percentage points more than iGlarLixi at 26 weeks, with a similar edge in fasting glucose. No significant differences were found in weight change.²⁷ A network meta-analysis found that both combination products beat their individual components for HbA1c reduction, but showed no significant difference between the two combinations themselves. iDegLira was associated with slightly less weight gain than iGlarLixi.²⁸ A direct comparison study of the two combinations found very similar HbA1c reductions, though a slightly higher proportion of iDegLira patients reached target, and weight loss was more favorable with iDegLira.²⁹

Concentrated Formulations

Both insulins come in concentrated versions. Tresiba is available in a 200 units/mL pen (Tresiba U200), and the Lantus molecule comes in a 300 units/mL version marketed as Toujeo (glargine U300). These concentrated forms are mainly useful for people who need large daily doses, because the smaller injection volume can improve how comfortably the insulin absorbs and make the injection itself less physically noticeable.³⁰ Tresiba U200 is bioequivalent to Tresiba U100 — same drug, same dose on the pen dial, just delivered in half the volume. Toujeo, however, is not simply concentrated Lantus; the higher concentration changes its absorption profile, giving it a flatter and somewhat longer action than standard Lantus U100. Comparing Tresiba to Toujeo is a slightly different question than comparing Tresiba to Lantus, and the trial data between those two products, while growing, is a separate body of evidence with its own nuances.

If you are weighing Tresiba against Lantus specifically, the bottom-line tradeoff is clear enough in the evidence: both lower blood sugar equally well, both cause similar weight gain, and both have reassuring cardiovascular safety profiles. Tresiba’s advantages are less hypoglycemia (especially at night), more consistent day-to-day blood sugar levels, and a more forgiving injection schedule. Lantus’s advantages are lower cost, wider availability of biosimilars, and a longer track record. Which of those tradeoffs matters most depends on your own blood sugar patterns, your schedule, and what your insurance will cover.